Furthermore, given the interplay between tumor-derived and stromal-derived chemokines, we propose that co-targeting of multiple chemokine pathways may be required in order to diminish multiple behavioral traits of aggressive PTEN-deficient prostate cancer cells. This evidence concerns the gene PTEN and prostate carcinoma.